

New Drug Approvals

Airsupra (albuterol and budesonide) Inhalation Aerosol

Company: AstraZeneca

Date of Approval: January 10, 2023

Treatment for: Asthma

Airsupra (albuterol and budesonide) is a beta 2-adrenergic agonist and corticosteroid fixed-dose combination rescue inhaler for as-needed use to reduce the risk of asthma exacerbations.

Leqembi (lecanemab-irmb) Injection

Company: Biogen Inc. and Eisai Co., Ltd.

Date of Approval: January 6, 2023

Treatment for: Alzheimer's Disease

Leqembi (lecanemab) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease.

Briumvi (ublituximab-xiyy) Injection

Company: TG Therapeutics, Inc.

Date of Approval: December 28, 2022

Treatment for: Multiple Sclerosis

Briumvi (ublituximab-xiyy) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.

NexoBrid (anacaulase-bcdb) Topical Gel

Company: MediWound Ltd.

Date of Approval: December 28, 2022

Treatment for: Burns, External

NexoBrid (anacaulase-bcdb) is a concentrate of proteolytic enzymes indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.

Information collected and compiled by

Md. Akbar Hossain

ASA University (ASAUB)

Shyamoli, Mohammadpur

Dhaka-1207, Bangladesh

Xenoview (xenon Xe 129 hyperpolarized) for Oral Inhalation

Company: Polarean Imaging plc

Date of Approval: December 23, 2022

Treatment for: Diagnosis and Investigation

Xenoview (xenon Xe 129 hyperpolarized) is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.

Sunlenca (lenacapavir) Injection and Tablets

Company: Gilead Sciences, Inc.

Date of Approval: December 22, 2022

Treatment for: HIV Infection

Sunlenca (lenacapavir) is a long-acting HIV-1 capsid inhibitor for use in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Lunsumio (mosunetuzumab-axgb) Injection

Company: Genentech, Inc.

Date of Approval: December 22, 2022

Treatment for: Follicular Lymphoma

Lunsumio (mosunetuzumab-axgb) is a bispecific CD20-directed CD3 T-cell engager for the treatment of relapsed or refractory follicular lymphoma.

Olpruva (sodium phenylbutyrate) for Oral Suspension - formerly ACER-001

Company: Acer Therapeutics Inc.

Date of Approval: December 22, 2022

Treatment for: Urea Cycle Disorders

Olpruva (sodium phenylbutyrate) is a nitrogen-binding agent for the treatment of patients with urea cycle disorders (UCDs).

References: www.drugs.com/news